Pretreatment CD34
Allogeneic stem cell transplantation
Myelodysplastic syndrome
Prognosis
Stem cells
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
15
01
2019
accepted:
19
03
2019
pubmed:
1
4
2019
medline:
22
7
2020
entrez:
1
4
2019
Statut:
ppublish
Résumé
Myelodysplastic syndrome (MDS) is a highly heterogeneous clonal hematopoietic disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment and is of particular interest in patients at high risk for progression to acute myeloid leukemia (AML). In MDS, CD34
Identifiants
pubmed: 30928626
pii: S1083-8791(19)30205-8
doi: 10.1016/j.bbmt.2019.03.022
pii:
doi:
Substances chimiques
Antigens, CD34
0
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1560-1566Informations de copyright
Copyright © 2019 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.